Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort.
Chen LM, Chang M, Dai Y, Chai KX, Dyrskjøt L, Sanchez-Carbayo M, Szarvas T, Zwarthoff EC, Lokeshwar V, Jeronimo C, Parker AS, Ross S, Borre M, Orntoft TF, Jaeger T, Beukers W, Lopez LE, Henrique R, Young PR, Urquidi V, Goodison S, Rosser CJ. Chen LM, et al. Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1804-12. doi: 10.1158/1055-9965.EPI-14-0029. Epub 2014 Jun 11. Cancer Epidemiol Biomarkers Prev. 2014. PMID: 24920641 Free PMC article.
Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer.
Fristrup N, Birkenkamp-Demtröder K, Reinert T, Sanchez-Carbayo M, Segersten U, Malmström PU, Palou J, Alvarez-Múgica M, Pan CC, Ulhøi BP, Borre M, Ørntoft TF, Dyrskjøt L. Fristrup N, et al. Am J Pathol. 2013 Feb;182(2):339-49. doi: 10.1016/j.ajpath.2012.10.017. Epub 2012 Nov 28. Am J Pathol. 2013. PMID: 23201130 Free article.
Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer.
Fristrup N, Ulhøi BP, Birkenkamp-Demtröder K, Mansilla F, Sanchez-Carbayo M, Segersten U, Malmström PU, Hartmann A, Palou J, Alvarez-Múgica M, Zieger K, Borre M, Ørntoft TF, Dyrskjøt L. Fristrup N, et al. Am J Pathol. 2012 May;180(5):1824-34. doi: 10.1016/j.ajpath.2012.01.023. Epub 2012 Mar 24. Am J Pathol. 2012. PMID: 22449953
Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines.
Schmitz-Dräger BJ, Kuckuck EC, Zuiverloon TC, Zwarthoff EC, Saltzman A, Srivastava A, Hudson MA, Seiler R, Todenhöfer T, Vlahou A, Grossman HB, Schoenberg MP, Sanchez-Carbayo M, Brünn LA, van Rhijn BW, Goebell PJ, Kamat AM, Roupret M, Shariat SF, Kiemeney LA. Schmitz-Dräger BJ, et al. Among authors: sanchez carbayo m. Urol Oncol. 2016 Oct;34(10):437-51. doi: 10.1016/j.urolonc.2016.05.030. Epub 2016 Sep 15. Urol Oncol. 2016. PMID: 27641313 Review.
Identification of PMF1 methylation in association with bladder cancer progression.
Aleman A, Cebrian V, Alvarez M, Lopez V, Orenes E, Lopez-Serra L, Algaba F, Bellmunt J, López-Beltrán A, Gonzalez-Peramato P, Cordon-Cardo C, García J, del Muro JG, Esteller M, Sánchez-Carbayo M. Aleman A, et al. Clin Cancer Res. 2008 Dec 15;14(24):8236-43. doi: 10.1158/1078-0432.CCR-08-0778. Clin Cancer Res. 2008. PMID: 19088041
Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer.
Schmitz-Dräger BJ, Todenhöfer T, van Rhijn B, Pesch B, Hudson MA, Chandra A, Ingersoll MA, Kassouf W, Palou J, Taylor J, Vlahou A, Behrens T, Critelli R, Grossman HB, Sanchez-Carbayo M, Kamat A. Schmitz-Dräger BJ, et al. Urol Oncol. 2014 Oct;32(7):1061-8. doi: 10.1016/j.urolonc.2013.10.010. Epub 2014 Jan 9. Urol Oncol. 2014. PMID: 24411790 Review.
Multiplexed methylation profiles of tumor suppressor genes in bladder cancer.
Cabello MJ, Grau L, Franco N, Orenes E, Alvarez M, Blanca A, Heredero O, Palacios A, Urrutia M, Fernández JM, López-Beltrán A, Sánchez-Carbayo M. Cabello MJ, et al. J Mol Diagn. 2011 Jan;13(1):29-40. doi: 10.1016/j.jmoldx.2010.11.008. Epub 2010 Dec 23. J Mol Diagn. 2011. PMID: 21227392 Free PMC article.
Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer.
Kamat AM, Vlahou A, Taylor JA, Hudson ML, Pesch B, Ingersoll MA, Todenhöfer T, van Rhijn B, Kassouf W, Barton Grossman H, Behrens T, Chandra A, Goebell PJ, Palou J, Sanchez-Carbayo M, Schmitz-Dräger BJ. Kamat AM, et al. Urol Oncol. 2014 Oct;32(7):1069-77. doi: 10.1016/j.urolonc.2014.06.017. Epub 2014 Oct 11. Urol Oncol. 2014. PMID: 25306288 Review.
Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.
Hutterer GC, Karakiewicz PI, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Serretta V, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Perrotte P, Lotan Y, Marberger MJ, Shariat SF. Hutterer GC, et al. BJU Int. 2008 Mar;101(5):561-5. doi: 10.1111/j.1464-410X.2007.07352.x. BJU Int. 2008. PMID: 18257856
104 results